IP Library Granted Patent US 12,016,889
Granted Patent B2
US 12,016,889 · App. 16/971,741 · Granted Jun 25, 2024

Compositions and methods for treating or preventing intestinal paracellular permeability

Inventor: Jay P. Madan (Raleigh, NC)
Assignee: 9 Meters Biopharma, Inc.
A61K35/741A61K35/76A61K38/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,016,889
App. No.
16/971,741
Granted
Jun 25, 2024
Kind
B2
Abstract

The present invention provides methods and compositions for maintaining and improving the integrity of gastrointestinal epithelial tight junctions, thereby helping to maintain healthy paracellular permeability of the GI epithelium. The present invention provides methods and compositions for the treatment or prevention of various conditions that are associated with gastrointestinal paracellular permeability, including various autoimmune conditions, inflammatory liver diseases, as well as inflammatory conditions of the large or small intestines.

Claims (15)

1. A microorganism comprising a polynucleotide encoding a peptide that consists of the amino acid sequence of larazotide (SEQ ID NO: 1), the polynucleotide further comprising a promoter controlling expression of the peptide,

wherein the microorganism is a species or strain naturally present in the duodenum and/or jejunum.

2. The microorganism of claim 1 , wherein the microorganism is a probiotic species.

3. The microorganism of claim 1 , wherein the microorganism is of the genus Saccharomyces, Lactobacillus, Clostridium, Streptococcus, Bifidobacterium, Enterococcus, Corynebacterium , or Candida.

4. The microorganism of claim 3 , wherein the microorganism is a species selected from Saccharomyces boulardii, Lactobacillus rhamnosus, Lactobacillus plantarum, Clostridium butyricum , non-toxigenic Clostridium difficile, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve, Candida albicans , and Streptococcus salivarius.

5. The microorganism of claim 1 , wherein the microorganism is a commensal microorganism.

6. The microorganism of claim 1 , wherein the polynucleotide further encodes a secretory signal at the N-terminus of the peptide.

7. A bacteriophage comprising a polynucleotide encoding a peptide that consists of the amino acid sequence of larazotide (SEQ ID NO: 1), the polynucleotide further comprising a promoter controlling expression of the peptide in a host bacteria,

wherein the bacteriophage infects a host bacteria naturally present in the duodenum and/or jejunum.

8. The bacteriophage of claim 7 , wherein the host bacteria is of the genus Lactobacillus, Clostridium, Streptococcus, Bifidobacterium, Enterococcus , or Corynebacterium.

9. The bacteriophage of claim 8 , wherein the host bacteria is a species selected from Lactobacillus rhamnosus, Lactobacillus plantarum, Clostridium butyricum , non-toxigenic Clostridium difficile, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve , and Streptococcus salivarius.

10. The bacteriophage of claim 7 , wherein the host bacteria is a commensal microorganism.

11. The bacteriophage of claim 7 , wherein the polynucleotide further encodes a secretory signal at the N-terminus of the peptide.

12. The bacteriophage of claim 7 , wherein the bacteriophage is lytic or lysogenic.

13. The bacteriophage of claim 7 , wherein the bacteriophage is of the order Caudovirales, Siphoviridae, Myoviridae, or Podoviridae.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2024
From: 9 METERS BIOPHARMA, INC.
To: EBRIS PHARMA CO.
Reel/Frame 067485/0533 →
CHANGE OF NAME Recorded May 21, 2024
From: EBRIS PHARMA CO.
To: INTERLUDE BIOPHARMA CO.
Reel/Frame 067486/0218 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 10, 2023
From: 9 METERS BIOPHARMA, INC.; NAIA RARE DISEASES, LLC
To: HIGH TRAIL SPECIAL SITUATIONS LLC
Reel/Frame 063281/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2020
From: MADAN, JAY
To: INNOVATE BIOPHARMACEUTICALS, INC.
Reel/Frame 053571/0047 →
CHANGE OF NAME Recorded Aug 24, 2020
From: INNOVATE BIOPHARMACEUTICALS, INC.
To: 9 METERS BIOPHARMA, INC.
Reel/Frame 053582/0215 →
Continuity (2)
Provisional Application 62634518 · Feb 23, 2018
Related Publication 20210030814A1 · Feb 4, 2021